- Boston Biomedical cancer stem cell pathway inhibitor stumbles in phase III trial
- Draft executive order not a complete wish list for biopharma
- Kala Pharmaceuticals eyes $86.25M IPO to prepare for commercial launch
- First test FDA-approved for use with multiple cancer drugs
- Tessa IDs biomarkers to predict efficacy of cyto...
SAN DIEGO – Data is the currency of the industry and masses of it are generated every day adding to the rapidly swelling repositories of public accessible and private databases around the world. The problem, however, remains that biopharma companies are whizzes at generating big data but this hasn't, as yet, helped them improve upon the number of new medicines that they bring over the goal line annually.
SAN DIEGO – Nobody wants to get old. Health declines, disease increases and insurance costs skyrocket. But what if researchers could slow the process at the cellular level, reverting stem cells to their youthful state, or clearing senescent cells, a hallmark of advanced years?
Two companies working in the space presented their research at the BIO convention during a session titled "Reimagine Old Age: New Frontiers in the Science of Aging."
The aging process involves a loss of homeostasis, with messy DNA and reduced gene expression.READ MORE »
- Stem cell treatment shows promise in severe spina bifida »
- Development to dementia, stem cells help understand the brain »
- Putting the liver to work makes quick bispecifics »
- Mitochondrial dysfunction leads to motor problems in fly model of Parkinson's »
- Viable new pain relief target identified in Australia »
- NGS maybe, sort of, sometimes clinic-ready »
- Statins overcome osteosarcoma metastasis and stemness »
- Potential therapeutic target pathway is identified in ALS »
- Chromatin state plays role in T cells' will to fight »
- Life and death and #BIO2017June 26, 2017 | 10:18 PM | Posted by: Marie Powers
- No choice, no free marketJune 20, 2017 | 6:35 PM | Posted by: Mari Serebrov
- Poverty, politics and preventable disease: Blurring the lines between truth and fiction in BioWorld’s 11th annual Summer Reading ListJune 01, 2017 | 4:13 PM | Posted by: Marie Powers
- Scientists don’t do politics … until nowApril 24, 2017 | 12:03 PM | Posted by: Nuala Moran
- Myth busters take on drug prices, or do they? April 04, 2017 | 1:35 AM | Posted by: Mari Serebrov
Partners in Focus
